Dopamine
| Clinical data |
| Routes of administration |
Intravenous
|
| Dosage |
- Predominant receptor activation is dose-dependent:
- <5 mcg/kg/min: Dopaminergic
- 5-10 mcg/kg/min: β-1 adrenergic
- >10 mcg/kg/min: α-1 adrenergic
- Low-dose dopamine should not be used for renal protective effect
- Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011 Apr 1;183(7):847-55. doi: 10.1164/rccm.201006-0972CI. Epub 2010 Nov 19. PMID: 21097695.
- Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000 Dec 23-30;356(9248):2139-43. doi: 10.1016/s0140-6736(00)03495-4. PMID: 11191541.
|
| Pharmacodynamics |
| Pharmacokinetics |
| Physical and chemical data |
| Article quality |
| Editor rating |
|
| User likes |
0 |
Provide a brief summary of this drug here.
Uses
Contraindications
Absolute contraindications
Precautions
Pharmacology
Pharmacodynamics
Mechanism of action
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
References